Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA by Quarter
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide sales ($M) ($M)
Johnson & Johnson PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA: $381M in Q3 2026, down 4.0% from a year earlier.
Where the Q3 2026 figure comes from
Source: Form 10-Q (filed 2026-10-21) ↗
Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
- PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — U.S. sales ($M)307 · Q3 2026
- PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — International sales ($M)74 · Q3 2026
- PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide reported growth YoY (%)-3.8% · Q3 2026
- PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide operational (constant-currency) growth YoY (%)-3.6% · Q3 2026
Cite this data
StockData. (2026). Johnson & Johnson PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA ($M), quarterly Q4 2016–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-prezista
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.